Histone Deacetylase Inhibitors Vorinostat and Panobinostat Induce G1 Cell Cycle Arrest and Apoptosis in Multidrug Resistant Sarcoma Cell Lines

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 5

PMID 29100385

Citations 26

Authors

Eva Bernhart

Nicole Stuendl

Heike Kaltenegger

Christian Windpassinger

Nicholas Donohue

Andreas Leithner

Birgit Lohberger

Affiliations

Soon will be listed here.

Abstract

Synovial sarcoma and high grade chondrosarcoma are characterized by their lack of response to conventional cytotoxic chemotherapy, the tendency to develop lung metastases, and low survival rates. Research within the field prioritizes the development and expansion of new treatment options for dealing with unresectable or metastatic diseases. Numerous clinical trials using histone deacetylases inhibitors (HDACi) have shown specific efficacy as an active antitumor agent for treating a variety of solid tumors. However, as of yet the effect of different HDACi on synovial- and chondrosarcoma cells has not been investigated. In this study, vorinostat (SAHA), panobinostat (LBH-589), and belinostat (PXD101) decreased cell viability of synovial sarcoma (SW-982) and chondrosarcoma (SW-1353) cells in a time- and dose dependent manner and arrested SW-982 cells in the G1/S phase. Western blot analysis determined the responsible cell cycle regulator proteins. In addition, we found apoptotic induction by caspase 3/7 activity, caspase 3 cleavage, and PARP cleavage. In SW-1353 cells only SAHA showed comparable effects. Noteworthy, all HDACi tested had synergistic effects with the topoisomerase II inhibitor doxorubicin in SW-1353 chondrosarcoma cells making the cells more sensitive to the chemotherapeutic drug. Our results show for the first time that SAHA and LBH-589 reduced viability of sarcoma cells and arrested them at the G1/S checkpoint, while also inducing apoptosis and enhancing chemotherapeutic sensitivity, especially in chondrosarcoma cells. These data demonstrate the exciting potential of HDACi for use in sarcoma treatment.

Citing Articles

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.

Li L, Hashemi L, Eid J, Tao W, Campoverde L, Yu A Int J Mol Sci. 2024; 25(23).

PMID: 39684713 PMC: 11641203. DOI: 10.3390/ijms252313003.

Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.

Noguchi R, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y Hum Cell. 2024; 38(1):28.

PMID: 39645627 DOI: 10.1007/s13577-024-01152-0.

The thiol methyltransferase activity of TMT1A (METTL7A) is conserved across species.

Gonzalez Dalmasy J, Fitzsimmons C, Frye W, Perciaccante A, Jewell C, Jenkins L Chem Biol Interact. 2024; 394:110989.

PMID: 38574836 PMC: 11056289. DOI: 10.1016/j.cbi.2024.110989.

Gesicles packaging dCas9-VPR ribonucleoprotein complexes can combine with vorinostat and promote HIV proviral transcription.

Fisher M, Chaudhry W, Campbell L Mol Ther Methods Clin Dev. 2024; 32(1):101203.

PMID: 38390557 PMC: 10881426. DOI: 10.1016/j.omtm.2024.101203.

The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors.

Robey R, Fitzsimmons C, Guiblet W, Frye W, Gonzalez Dalmasy J, Wang L Mol Cancer Ther. 2023; 23(4):464-477.

PMID: 38151817 PMC: 11223745. DOI: 10.1158/1535-7163.MCT-23-0144.

References

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

Sarfstein R, Bruchim I, Fishman A, Werner H . The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One. 2011; 6(9):e24468. PMC: 3169604. DOI: 10.1371/journal.pone.0024468. View

Robert C, Rassool F . HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 2012; 116:87-129. DOI: 10.1016/B978-0-12-394387-3.00003-3. View

Yoo C, Jones P . Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5(1):37-50. DOI: 10.1038/nrd1930. View

Damron T, Ward W, Stewart A . Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007; 459:40-7. DOI: 10.1097/BLO.0b013e318059b8c9. View

Stiborova M, Eckschlager T, Poljakova J, Hrabeta J, Adam V, Kizek R . The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem. 2012; 19(25):4218-38. DOI: 10.2174/092986712802884286. View

Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M . The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer. 2013; 13:286. PMC: 3693872. DOI: 10.1186/1471-2407-13-286. View

West A, Johnstone R . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. PMC: 3871231. DOI: 10.1172/JCI69738. View

Drummond D, Noble C, Kirpotin D, Guo Z, Scott G, Benz C . Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005; 45:495-528. DOI: 10.1146/annurev.pharmtox.45.120403.095825. View

10.

Rosato R, Almenara J, Dai Y, Grant S . Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia.... Mol Cancer Ther. 2004; 2(12):1273-84. View

11.

Obaya A, Sedivy J . Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002; 59(1):126-42. PMC: 11337483. DOI: 10.1007/s00018-002-8410-1. View

12.

Linch M, Miah A, Thway K, Judson I, Benson C . Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol. 2014; 11(4):187-202. DOI: 10.1038/nrclinonc.2014.26. View

13.

Chugh R, Dunn R, Zalupski M, Biermann J, Sondak V, Mace J . Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005; 23(15):3597-604. DOI: 10.1200/JCO.2005.02.170. View

14.

Ma T, Galimberti F, Erkmen C, Memoli V, Chinyengetere F, Sempere L . Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther. 2013; 12(8):1545-55. PMC: 3742691. DOI: 10.1158/1535-7163.MCT-12-0933. View

15.

Vlenterie M, Jones R, van der Graaf W . Synovial sarcoma diagnosis and management in the era of targeted therapies. Curr Opin Oncol. 2015; 27(4):316-22. DOI: 10.1097/CCO.0000000000000198. View

16.

Singh T, Shankar S, Srivastava R . HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005; 24(29):4609-23. DOI: 10.1038/sj.onc.1208585. View

17.

Arellano M, Moreno S . Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol. 1997; 29(4):559-73. DOI: 10.1016/s1357-2725(96)00178-1. View

18.

Sonnemann J, Marx C, Becker S, Wittig S, Palani C, Kramer O . p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer. 2013; 110(3):656-67. PMC: 3915118. DOI: 10.1038/bjc.2013.742. View

19.

Borden E, Amato D, Edmonson J, Ritch P, Shiraki M . Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990; 66(5):862-7. DOI: 10.1002/1097-0142(19900901)66:5<862::aid-cncr2820660509>3.0.co;2-r. View

20.

Prince H, Bishton M, Johnstone R . Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009; 5(5):601-12. DOI: 10.2217/fon.09.36. View